title: Novel therapies for hepatitis C - one pill fits all?
abstract: Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense research and development efforts, a large number of direct-acting antiviral drugs are now beginning to reach patient care. Accordingly, the way in which care is delivered is evolving at a breath-taking pace. Here, we review the current and upcoming treatment options for HCV, describe the key challenges facing clinicians and drug developers and discuss how the landscape in the HCV arena will change over the coming years.
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany. manns.michael@ mh-hannover.de
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
authors.forename: Thomas
authors.initials: T
authors.lastname: von Hahn
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D018937:Hepatitis C Antibodies